Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.

Largest Real-World Evidence (RWE) Analysis of Yescarta in Second-Line Shows 71% Overall Survival Rate, Consistent with Pivotal ZUMA-7 Study, in Broader Patient Population with Relapsed/Refractory ...

Real-world evidence from the largest analysis of second-line treatment with Yescarta in 2022-2023 demonstrated a high overall survival rate in patients with relapsed/refractory large b-cell lymphoma.

Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta®(axicabtagene ciloleucel) that demonstrate improved outcomes for people living with ...

The company states: “Kite, a Gilead (GILD) Company, announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta in patients with relapsed/refractory non-Hodgkin ...

Curocell launches Limcato, South Koreas first domestic CAR-T cancer therapy Curocell introduces first local CAR-T therapy, ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novartis ...